Unichem Labs’ share price jumps 4% amid US generics consolidation plans

Unichem Laboratories has made headlines recently. During Monday's intraday trading, its share price increased by 4.15% to reach ₹671.55 on the Bombay Stock Exchange (BSE). This rise follows the company's announcement regarding the integration of its US generic formulations.

Plans for consolidation of generics business

In an exchange filing, Unichem Laboratories revealed that the Board of Directors meeting will take place on September 30, 2024, to discuss the consolidation of its generics formulations business in the United States. This move involves merging its US subsidiary, Unichem Pharmaceuticals (USA) Inc., with Bayshore Pharmaceuticals LLC, a wholly-owned subsidiary of Ipca Laboratories Limited, which holds a majority stake in Unichem. The aim is to streamline all of Ipca Group's generics operations in the US under a single entity, enhancing efficiency and operational synergies.

Ipca Laboratories’ influence on Unichem

Alongside Unichem's rise, shares of Ipca Laboratories also increased by 1.14%, trading at ₹1,450.05 per share. Ipca's acquisition of a controlling stake in Unichem has been pivotal; it purchased 33.38% of Unichem's equity in August 2023 and followed up with an additional 19.29% by September 2023. This raised its total shareholding to 52.67%, a move that received clearance from the Competition Commission of India (CCI) in July 2023.

Overview of Unichem Laboratories

Unichem Laboratories is a prominent domestic pharmaceutical company based in Mumbai. It is known for manufacturing active pharmaceutical ingredients (APIs). The firm operates through four divisions: Unichem Pharma Division, Unichem Specialities Division, Unisearch Division, and Neu-Foreva Division. With five manufacturing facilities, Unichem boasts a market capitalisation of ₹4,642 crore, according to BSE data.

Financial performance

Despite the recent surge, Unichem's shares currently trade at a price-to-earnings (P/E) ratio of -82.54, reflecting earnings per share (EPS) of ₹-7.81. Over the past year, the stock has seen fluctuations, with a 52-week high of ₹693.25 and a low of ₹398.70. As of 11:11 AM on the trading day, shares were valued at ₹659.40. In comparison, the BSE Sensex rose by 0.23%, reaching 84,741 points.

Key takeaways

• Unichem Laboratories' share price increased by 4.15% following its announcement of plans to consolidate US generics formulations.
• The company will integrate its US operations with Bayshore Pharmaceuticals LLC under its subsidiary, Unichem Pharmaceuticals (USA) Inc.
• Ipca Laboratories, the majority shareholder in Unichem, also saw its shares rise, benefiting from the consolidation.
• Unichem Laboratories manufactures active pharmaceutical ingredients and operates through four divisions, with a market cap of ₹4,642 crore.
• The company’s shares trade at a negative P/E ratio, indicating current financial challenges despite recent price increases.

If you're interested in the pharmaceutical sector and wish to buy shares online, consider monitoring Unichem Laboratories as it embarks on this strategic consolidation journey.